Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Herceptin Helps Women With Multiple Chromosomes Containing HER2 Gene

18.12.2007
The targeted therapy Herceptin helps women with HER2+ type of breast cancer independent of whether patients have extra copies of chromosome 17, home to the HER2 gene which produces the HER2 protein that fuels cancer growth. Prior to this report, there were conflicting opinions about whether that was the case, say Mayo Clinic investigators who presented their findings at the San Antonio Breast Cancer Symposium.

The analysis came from the North Central Cancer Treatment Group's clinical trial N9831 which tested the use of Herceptin in combination with chemotherapy in patients with surgically-removed HER2+, early-stage, node-positive or high-risk, node-negative breast cancer. Data from the trial on the long term efficacy and safety of this treatment were presented recently by Mayo Clinic researchers and collaborators as part of a joint analysis with another U.S. trial. They demonstrated the significant benefit of using Herceptin, which is a monoclonal antibody that binds the HER2 protein, shutting down its function.

HER2+ breast cancer accounts for approximately 20 percent of all breast cancer cases, and most oncologists decide whether to use Herceptin based on a test that measures the amount of HER2 protein or the number of extra ("amplified") genes in a patient's tumor tissue sample. The goal of this sub-study was to see if patients with more than two chromosome 17s (known as polysomy 17) had a different outcome from use of Herceptin.

"Some oncologists thought that patients with non-amplified HER2 gene in polysomy 17 tumors may respond to Herceptin because they may have that many extra HER2 genes resulting in HER2 protein over expression. Others thought they might not benefit because they had far too many HER2 genes from the extra chromosomes, producing too much HER2 protein, which may overwhelm Herceptin's effectiveness," says the study's lead investigator, Monica M. Reinholz, Ph.D., an assistant professor at Mayo Clinic's campus in Rochester, Minn. "No one knew if they would respond, in general, or not."

The research team, led by Edith A. Perez, M.D., from the Mayo Clinic campus in Jacksonville, Fla., specifically found that 865 patients had HER2 gene amplified tumors with polysomy 17 and 685 women had amplification with two copies (normal) of chromosome 17 did equally well using Herceptin. Their disease-free survival was about 89 percent three years after treatment and between 88 percent and 89 percent five years after therapy, Dr. Reinholz says. "These results of this new analysis suggest that chromosome 17 number status is not predictive of Herceptin response in patients with HER2 amplified tumors," she says.

Also, they found that women with HER2 gene amplification and polysomy 17 who were treated only with chemotherapy seemed to have had a better outcome than patients treated with chemotherapy who did not have the extra chromosomes. Three-year disease-free survival was 83 percent and 75 percent, respectively, and five-year disease-free survival was 78 percent and 68 percent. "This is an interesting and unexpected finding," Dr. Reinholz says.

Researchers also found that 37 patients had HER2 non-amplified and polysomy 17 tumors, and 67 patients had HER2 non-amplified and normal chromosome 17 tumors. There was no apparent influence of polysomy 17 in predicting Herceptin benefit in women with HER2 non-amplified tumors, they say. However, due to the small number of cases in this study, additional patients will be needed to determine whether Herceptin is beneficial in patients with non-amplified HER2 tumors, the researchers say.

The study was funded by Genentech and the Breast Cancer Research Foundation.

Paul Scotti | EurekAlert!
Further information:
http://www.mayoclinic.org/news

More articles from Health and Medicine:

nachricht Inselspital: Fewer CT scans needed after cerebral bleeding
20.03.2019 | Universitätsspital Bern

nachricht Building blocks for new medications: the University of Graz is seeking a technology partner
19.03.2019 | Karl-Franzens-Universität Graz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New gene potentially involved in metastasis identified

Gene named after Roman goddess Minerva as immune cells get stuck in the fruit fly’s head

Cancers that display a specific combination of sugars, called T-antigen, are more likely to spread through the body and kill a patient. However, what regulates...

Im Focus: The taming of the light screw

DESY and MPSD scientists create high-order harmonics from solids with controlled polarization states, taking advantage of both crystal symmetry and attosecond electronic dynamics. The newly demonstrated technique might find intriguing applications in petahertz electronics and for spectroscopic studies of novel quantum materials.

The nonlinear process of high-order harmonic generation (HHG) in gases is one of the cornerstones of attosecond science (an attosecond is a billionth of a...

Im Focus: Magnetic micro-boats

Nano- and microtechnology are promising candidates not only for medical applications such as drug delivery but also for the creation of little robots or flexible integrated sensors. Scientists from the Max Planck Institute for Polymer Research (MPI-P) have created magnetic microparticles, with a newly developed method, that could pave the way for building micro-motors or guiding drugs in the human body to a target, like a tumor. The preparation of such structures as well as their remote-control can be regulated using magnetic fields and therefore can find application in an array of domains.

The magnetic properties of a material control how this material responds to the presence of a magnetic field. Iron oxide is the main component of rust but also...

Im Focus: Self-healing coating made of corn starch makes small scratches disappear through heat

Due to the special arrangement of its molecules, a new coating made of corn starch is able to repair small scratches by itself through heat: The cross-linking via ring-shaped molecules makes the material mobile, so that it compensates for the scratches and these disappear again.

Superficial micro-scratches on the car body or on other high-gloss surfaces are harmless, but annoying. Especially in the luxury segment such surfaces are...

Im Focus: Stellar cartography

The Potsdam Echelle Polarimetric and Spectroscopic Instrument (PEPSI) at the Large Binocular Telescope (LBT) in Arizona released its first image of the surface magnetic field of another star. In a paper in the European journal Astronomy & Astrophysics, the PEPSI team presents a Zeeman- Doppler-Image of the surface of the magnetically active star II Pegasi.

A special technique allows astronomers to resolve the surfaces of faraway stars. Those are otherwise only seen as point sources, even in the largest telescopes...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

International Modelica Conference with 330 visitors from 21 countries at OTH Regensburg

11.03.2019 | Event News

Selection Completed: 580 Young Scientists from 88 Countries at the Lindau Nobel Laureate Meeting

01.03.2019 | Event News

LightMAT 2019 – 3rd International Conference on Light Materials – Science and Technology

28.02.2019 | Event News

 
Latest News

Listening to the quantum vacuum

26.03.2019 | Physics and Astronomy

The struggle for life in the Dead Sea sediments: Necrophagy as a survival mechanism

26.03.2019 | Earth Sciences

Mangroves and their significance for climate protection

26.03.2019 | Earth Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>